Skip to main content
. 2002 Feb;160(2):693–700. doi: 10.1016/S0002-9440(10)64889-4

Table 2.

Incidence and Pathology of Tumors Produced by Orthotopic Injection of MYU-3L and Transfected Cells

Cells* Tumor incidence Time blood first detected in urine, range (days) Latent period, range (days) Duration of experiment, range (days) Incidence of metastasis
Controls and cells with less than three-fold induction of S100A4 mRNA
MYU-3L (parent line) 15 /15 20 (14–29) 22 (14–34) 42 (31–70) 0 /15
MYU-P§ 9 /10 11 (5–22) 13 (9–18) 41 (28–58) 0 /9
MYU-plasmid 12 /12 25 (19–33) 23 (20–25) 43 (36–49) 0 /12
MYU-C6 8 /8 ND 18 (11–24) 49 (39–57) 0 /8
MYU-C2 6 /6 17 (17–18) 19 (15–24) 36 (28–47) 0 /6
Totals 50 /51 16 (5–33) 20 (9–34) 42 (28–70) 0 /50
Cells with at least 4-fold induction of S100A4 mRNA:
MYU-C7 8 /8 25 (19–33) 22 (15–25) 44 (28–59) 2 /8
MYU-C14 9 /9 25 (12–35) 17 (12–22) 39 (31–51) 2 /9
Totals 17 /17 25 (12–35) 19 (12–25) 41 (28–59) 4 /17**

*One to 2 × 106 cells injected into the bladder wall.

No. of animals with tumors/no. of animals injected.

No. of animals with metastases/no. of animals with tumors.

§MYU-3L cells cultured from a nonmetastatic primary tumor and reinjected into a further group of animals.

MYU-3L cells transfected with pSV2neo plasmid vector alone.

ND, not determined.

**Significantly more metastases than controls and cells with less than three-fold induction of S100A4 mRNA (P < 0.05; Fisher’s exact test).